YUMM1.7 Mouse Melanoma Cell Line

Source:
The YUMM1.7 mouse melanoma cell line was derived from a 4-hydroxytamoxifen-induced melanoma tumor in a male C57/B1/6 mouse into which mutations from the Braf/Pten genetically-engineered mouse model had been introduced via backcrossing. The YUMM1.7 cell line harbors the Braf V600E mutation and is homozygous negative for wild-type Pten and Cdkn2 (1).

The great promise of immune-based therapies in cancer and recent progress in successful application of these approaches has brought to the fore the necessity of immune-competent models to evaluate immune system responses to cancer cells. Immunocompetent genetically-engineered mouse models harboring discrete genetic drivers of melanoma are essential for studying potential immunotherapies but are limited by the need to maintain colonies of multiple genotypes necessary to generate mouse models with appropriate genetic backgrounds.

The YUMM1.7 mouse melanoma cell line was developed as an immunocompetent cell line that recapitulates genetic drivers found in a significant proportion of human melanomas (1). YUMM1.7 cells are syngeneic with the immunocompetent C57/B1/6 mouse background and retain genetic markers of the Braf/Pten mouse model, characterized by activation of Braf and inactivation of Pten and Cdkn2a, in which melanoma tumors develop with short latency (2). YUMM1.7 cells are highly tumorigenic in vivo (1). The YUMM1.7 mouse melanoma cell line represents a valuable tool for tumor immunology and cancer biology, especially tractable for the evaluation and generation of new immunotherapies.

References:
1. Meeth K et al. (2016) The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations. Pigment Cell Melanoma Res 29(5): 590-597.
2. Dankort D et al. (2009) Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet. 41(5): 544-552.

Subject to local law, this product is intended to be sold for internal in vitro research use only subject to terms and conditions found here: www.sigmaaldrich.com/restrictedcelluse. This product may not be: re-engineered or copied; used to make derivatives, modifications or functional equivalents; used to obtain patents or other IP claiming use of the product; used to develop, test, or manufacturer a commercial product; used as a component in a commercial product; resold or licensed; used in any clinical applications or trials; or used in humans. A license or limited commercial use agreement is required for use by any for-profit entity, use in services, and use in sponsored academic research. For information regarding any such use, please contact licensing@milliporesigma.com.

Store in liquid nitrogen. The cells can be cultured for at least 10 passages after initial thawing without significantly affecting the cell marker expression and functionality.

This product contains genetically modified organisms (GMO). Within the EU GMOs are regulated by Directives 2001/18/EC and 2009/41/EC of the European Parliament and of the Council and their national implementation in the member States respectively. This legislation obliges {HCompany} to request certain information about you and the establishment where the GMOs are being handled. Click here for Enduser Declaration (EUD) Form.Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.